Acetyl-CoA carboxylase

亜型選択性的な製品

Acetyl-CoA carboxylase製品

  • All (8)
  • Acetyl-CoA carboxylase阻害剤 (7)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S8893 Firsocostat (GS-0976, ND-630) Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.
Nat Commun, 2023, 14(1):1362
Genome Med, 2022, 14(1):67
Sci Adv, 2022, 8(47):eabq1984
S6753 CP 640186 CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.
Exp Ther Med, 2020, 20(1):521-529
Molecules, 2015, 20(9):16221-34
Molecules, 2015, 20(9):16221-34
S8377 ND646 ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.
Cancer Discov, 2023, 13(2):496-515
Cancer Sci, 2023, 114(4):1651-1662
Cancer Sci, 2023, 114(4):1651-1662
S6690 TOFA TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.
bioRxiv, 2024, 2024.02.22.581432
Cancer Commun (Lond), 2022, 10.1002/cac2.12380
Sci Adv, 2021, 7(35)eabj0364
S6672 PF-05175157 PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.
Cancer Cell Int, 2023, 23(1):83
S5519 4-Methylsalicylic acid 4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145 PF-05221304 PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).
S6112 Oxalacetic acid Oxalacetic acid (Oxaloacetic acid, 2-Oxosuccinic acid, Ketosuccinic acid) is an intermediate of the citric acid cycle, where it reacts with acetyl-CoA to form citrate, catalysed by citrate synthase. It is also involved in gluconeogenesis, urea cycle, glyoxylate cycle, amino acid synthesis, and fatty acid synthesis. Oxaloacetate is also a potent inhibitor of Complex II.
S8893 Firsocostat (GS-0976, ND-630) Firsocostat (GS-0976, ND-630) is a reversible inhibitor of acetyl CoA carboxylase (ACC) with IC50s of 2.1 nM,6.1 nM for hACC1 and hACC2,respectively.
Nat Commun, 2023, 14(1):1362
Genome Med, 2022, 14(1):67
Sci Adv, 2022, 8(47):eabq1984
S6753 CP 640186 CP 640186 is an isozyme-nonselective ACC (Acetyl-CoA carboxylase) inhibitor with IC50 values of 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively.
Exp Ther Med, 2020, 20(1):521-529
Molecules, 2015, 20(9):16221-34
Molecules, 2015, 20(9):16221-34
S8377 ND646 ND-646 is an allosteric inhibitor of the ACC (Acetyl-coA carboxylase) enzymes that prevents ACC subunit dimerization to suppress fatty acid synthesis with IC50 of 3.5 nM and 4.1 nM for hACC1 and hACC2, respectively.
Cancer Discov, 2023, 13(2):496-515
Cancer Sci, 2023, 114(4):1651-1662
Cancer Sci, 2023, 114(4):1651-1662
S6690 TOFA TOFA is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA). Inside the cell, TOFA is converted to TOFyl-CoA (5-tetradecyloxy-2-furoyl-CoA), exerting an allosteric inhibition on ACCA. TOFA blocks fatty acid synthesis and induces cell death in a dose-dependent manner.
bioRxiv, 2024, 2024.02.22.581432
Cancer Commun (Lond), 2022, 10.1002/cac2.12380
Sci Adv, 2021, 7(35)eabj0364
S6672 PF-05175157 PF-05175157 is a broad-spectrum effective ACC inhibitor with IC50 of 27.0 nM, 33.0 nM, 23.5 nM and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively.
Cancer Cell Int, 2023, 23(1):83
S5519 4-Methylsalicylic acid 4-Methylsalicylic acid (m-Cresotic acid, 2-Hydroxy-4-methylbenzoic acid, m-Cresotinic acid, 2-Hydroxy-p-toluic acid) is used to inhibit the medium chain acyl-CoA synthetase.
S6145 PF-05221304 PF-05221304 is an orally bioavailable, liver-targeted inhibitor of acetyl-CoA carboxylase (ACC), an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL).

Acetyl-CoA carboxylase阻害剤の選択性比較

Tags: Acetyl-CoA carboxylase inhibitor|Acetyl-CoA carboxylase agonist|Acetyl-CoA carboxylase activator|Acetyl-CoA carboxylase inducer|Acetyl-CoA carboxylase antagonist|Acetyl-CoA carboxylase signaling pathway|Acetyl-CoA carboxylase assay kit